Home About Our Mission ReSearch & Tech Meet The Team Contact Invest
Investment Opportunity

Building an
AI-Assisted CMC
Intelligence Platform

NeurAeon Technologies is developing an AI-augmented platform designed to help virtual biotechs, CDMOs, formulation groups, and early-stage development teams identify process-chemistry and CMC risks earlier, organize technical reasoning more clearly, and produce structured pre-lab documentation before expensive laboratory, scale-up, or regulatory decisions are made.

Explore The Solution
NeurAeon Research Laboratory
Pre-Validation
Prototype Stage

Positioning

We are not building an autonomous chemistry engine, a replacement for process chemists, or a substitute for wet-lab validation.

NeurAeon is being designed as a bounded, auditable, human-governed intelligence layer that supports qualified experts by making early development risks easier to see, review, document, and act on.

The Problem

Early pharmaceutical development is expensive, fragmented, and heavily dependent on scarce senior expertise.

Virtual biotech teams and smaller CDMOs often face recurring bottlenecks around route scouting, impurity reasoning, process-risk review, analytical-control planning, and CMC documentation. These workflows are typically spread across literature searches, consultant input, internal review, CDMO communication, spreadsheets, emails, and technical documents.

The result is slow iteration, inconsistent documentation, delayed risk visibility, and expensive downstream surprises.

Slow
Iteration Cycles
Inconsistent
Documentation
Delayed
Risk Visibility
Expensive
Downstream Surprises

The Solution

NeurAeon’s platform is built around Agentic-AI orchestration: a structured workflow in which specialized AI agents review scientific inputs through defined stages, while deterministic controls, human approval gates, claim boundaries, and audit trails keep the system bounded, reviewable, and accountable.

Structured Review

Guide molecule or route-related input through retrosynthesis, process-risk analysis, impurity profiling, scalability concerns, analytical-control gaps, and regulatory documentation readiness.

Deterministic Controls

Each layer governed by structured output schemas, claim ceilings, literature-grounding requirements, human review gates, and an append-only audit trail.

Human Governed

The goal is not to let AI freely generate scientific conclusions. The goal is to constrain AI inside a disciplined workflow that qualified humans can inspect, challenge, approve, or reject.

NeurAeon is focused on the gap between a promising candidate molecule and a clearer, more structured, CDMO-ready development package.

What NeurAeon Helps Teams Do

Review Literature

Review literature-grounded route options with structured comparative analysis.

Flag Concerns

Flag process chemistry and scale-up concerns before resource commitment.

Identify Risks

Identify impurity and analytical-control risks through predictive profiling.

Organize CMC

Organize early CMC reasoning into structured, reviewable formats.

Produce Packages

Produce structured pre-lab documentation packages for stakeholder review.

Maintain Audit Trail

Maintain a clear decision trail for expert review and regulatory readiness.

Current Stage

NeurAeon is currently in the pre-validation, prototype-to-validation stage.

Our near-term focus is to complete a working demonstration prototype that shows the workflow operating end-to-end on public, well-known molecules. This prototype is intended to demonstrate the architecture, user flow, governance gates, audit trail, and structured output behavior.

Scientific validation comes next. The key credibility milestone is Digital Shadow validation, where the platform will be tested against historical APIs with known published routes and known failure modes. The purpose of that work is to measure performance honestly before the platform is positioned for serious customer use.

Until validation metrics exist, we describe NeurAeon accurately: a focused, high-potential, pre-validation pharmaceutical intelligence platform with a disciplined roadmap toward technical credibility.

What We Are Seeking

NeurAeon is seeking aligned investors, advisors, and strategic partners who understand the importance of disciplined execution in regulated scientific software.

Capital Deployment

Capital will support the transition from architecture and prototype into a validated platform foundation.

Scientific Advisory

Process chemistry and regulatory CMC expertise to evaluate outputs, identify failure modes, and refine technical boundaries.

Primary Funding Priorities

Deterministic Backbone
AI Agent Integration
PhD Chemist Recruitment
Regulatory CMC Support
Digital Shadow Validation
Initial IP Review
Design-Partner Discovery
Compliance Infrastructure

Near-Term Milestones

Our execution roadmap is built around credibility, not hype.

01

Demonstration Prototype

Show the Agentic-AI Orchestration workflow operating end-to-end with molecule input, agent review, human governance gates, structured outputs, and audit-log visibility.

02

Deterministic Backbone

Build the trust layer: schema enforcement, claim ceilings, state-machine logic, forbidden-claim controls, literature grounding, and append-only audit logging.

03

Expert Review

Bring in process chemistry and regulatory CMC expertise to evaluate the system's outputs, identify failure modes, and refine technical boundaries.

04

Digital Shadow Validation

Run the system against historical APIs and score its ability to flag known risks, avoid unsupported claims, and produce complete documentation packages.

05

Design-Partner Pilots

Engage selected virtual biotech and CDMO partners once validation evidence and expert review support the platform's credibility.

06

First Paid Customers

Convert validated pilot use cases into early commercial relationships with documented ROI and referenceable outcomes.

Differentiation

The pharmaceutical industry does not need another generic AI chatbot.

It needs disciplined, auditable, human-governed systems that can operate inside complex development workflows without overstating what AI can do. NeurAeon is being built around that principle.

Our long-term vision is to become a trusted pharmaceutical development intelligence layer: a system that helps teams see risks earlier, structure decisions more clearly, preserve scientific reasoning, and improve the quality of early CMC and process-development preparation.

The opportunity is significant, but the path is precise: prototype, validate, earn trust, pilot, and scale.

Contact

For investor inquiries, advisor conversations, or strategic partnership discussions:

Founder & CEO
Jordan Matthew Schleicher
Location
Kansas City, Missouri
Email
jordan@neuraeon.org
Phone
(816) 647-5512